BRIDION®

Drug Information Related Patent
Hold Company
MERCK SHARP DOHME
Learn More
Dosage and Administration
SOLUTION;INTRAVENOUS
Specification
EQ 500MG BASE/5ML (EQ 100MG BASE/ML); EQ 200MG BASE/2ML (EQ 100MG BASE/ML)
Indication
BRIDION® is indicated for reversal of neuromuscular blockade caused by rocuronium and vecuronium in adult and pediatric patients 2 years of age and older undergoing surgery.
Use
Instructions for Use
API
SUGAMMADEX SODIUM
API Structure
We Supply
SUGAMMADEX SODIUM
Note:

USP/CP/EP
Facility GMP
USMF/ASMF/CDE/DMF

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
RE447332026/1/27
API Patent
Patent NoExpiration Date
RE447332026/1/27
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen-ING. All Rights Reserved.
dcat
Member of
dcat
Top